Company Description
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs.
In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.
Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025.
Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
| Country | United States |
| Founded | 2009 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Joshua Riggs |
Contact Details
Address: 2 International Plaza Dr., Suite 510 Nashville, Tennessee 37217 United States | |
| Phone | 949 409 7600 |
| Website | imdxinc.com |
Stock Details
| Ticker Symbol | IMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C206 |
| ISIN Number | US68235C2061 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc. |
| Joshua Riggs | President, Chief Executive Officer and Director |
| Andrea Susan James | Chief Financial Officer |
| James Liu | Vice President of Accounting, Treasurer, Controller and Principal Accounting Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Peter Hong | Vice President, General Counsel and Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
| Dr. Paul R. Billings FACP, M.D., Ph.D. | Consulting Chief Medical Officer |
| Gabrielle Woody | Senior Executive Assistant |